查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
即时 (POC) 基因检测市场：2023 年至 2028 年预测
市场调查报告书
商品编码
1410110

即时 (POC) 基因检测市场：2023 年至 2028 年预测

Point-of-Care Genetic Testing Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计在预测期内，即时护理 (POC) 基因检测市场将以 12.08% 的复合年增长率成长。

随着技术进步使基因检测能力更接近患者的护理点，护理点 (POC) 基因检测市场正在迅速扩大。即时检测 (POC) 基因检测是在标准实验室之外进行的基因检测，可实现即时观察和决策。这个市场类别包括各种测试设备和套件，使医疗保健专业人员能够快速分析遗传资料并做出明智的治疗决策。对个体化治疗、早期疾病诊断和轻鬆获得基因检测的需求不断增长，正在推动即时 (POC) 基因检测市场的发展。此外，便携式和手持式检测技术的市场开拓以及基因检测价格的下降正在推动市场扩张。即时护理 (POC) 基因检测市场的成长为医疗保健服务的彻底变革提供了广阔的前景，因为它能够改善患者的治疗结果并实现个体化治疗方法。

即时（POC）基因检测市场对个人化医疗和精准医疗的需求不断增长

对个体化和精准治疗日益增长的需求正在推动即时护理 (POC) 基因检测市场的发展。个人化医疗和精准医疗涉及根据遗传、生活方式和环境因素对每位患者进行个体化医疗。这种方法可以实现更准确的诊断、量身定制的治疗和更好的治疗结果。随着患者和医疗保健提供者认识到个人化医疗提供更有效和个体化治疗的承诺，对能够在治疗时提供快速、准确的遗传资讯的基因检测技术的需求正在增加。收集准确的基因资料的能力使医疗保健提供者能够就治疗策略、药物选择和预防措施做出明智的决策，从而推动对即时 (POC) 基因检测解决方案的需求。我就是。

对遗传疾病的认识和理解不断提高，加强了即时 (POC) 基因检测市场

对遗传疾病的认识和了解不断增加是推动即时（POC）基因检测产业成长的主要因素。随着大众对基因突变对健康影响的了解不断扩大，个人和医疗保健专业人员在检测和管理遗传疾病方面变得更加积极主动。教育工具、公众意识宣传活动和遗传咨询服务都有助于更好地了解遗传疾病。这种知识的增加促进了资讯资讯诊断、个性化治疗方法和明智的决策。这一需求正在不断增长。医疗保健领域对遗传疾病的日益关注导致基因检测的使用范围扩大，推动了即时 (POC) 基因检测市场的成长。

即时检测能力的扩展将推动即时（POC）基因检测市场的发展

床边检测能力的扩展是床边检测（POC​​）基因检测市场成长的关键驱动力。即时护理测试是指在患者附近进行诊断测试并提供即时资料以帮助紧急决策。随着技术的进步，POC 检测设备的性能得到提高，使得在护理点进行更复杂的基因检测成为可能。这项进步使医护人员能够接收即时遗传资讯，而无需将样本提交给中央检测机构。能够进行先进基因分析的便携式和手持式诊断设备的出现增加了便利性，减少了周转时间，并改善了患者的治疗结果。床边检测能力的增强使医护人员能够做出更快、更资讯的决策，从而推动了对床边 (POC) 基因检测解决方案的需求。我就是。

北美是即时护理（POC）基因检测市场的领导者

北美已成为即时检测 (POC) 基因检测市场的领导者。有几个因素促成了该地区的主导地位。北美医疗体系技术先进，遗传性疾病发生率高，强调个体化治疗。此外，该地区还受益于研发方面的高额支出、医疗机构和技术公司之间的合作以及鼓励使用即时护理 (POC) 基因检测的有利法律规章。主要市场参与者的存在以及现代测试设备和套件的可用性有助于北美的优势。但值得注意的是，全球即时检测（POC​​）基因检测的市场规模正在扩大，欧洲和亚太等其他地区也看到了该产业的重大突破。

即时检测 (POC) 基因检测市场的快速结果和及时决策

在即时检测 (POC) 基因检测业务中，快速发现和快速决策是关键。传统的基因检测需要将样本运送到中央设施，这可能会延迟获得观察。另一方面，即时护理 (POC) 基因检测的优点是可以在患者所在地快速提供观察，使医疗保健专业人员能够快速做出选择。如此快速的反应可以实现快速介入、个体化治疗策略和更好的患者治疗效果。及时获取遗传资讯的能力可以提高医疗服务的效率，减少患者等待观察的时间，并能够快速做出有关治疗方案、预防措施和咨询的决策。快速观察和快速决策是在各种医疗保健环境中使用即时护理 (POC) 基因检测技术的重要动机。

主要进展

  • 2022 年 8 月，生命科学研究和临床诊断产品领域的全球领导者 Bio-Rad Laboratories 宣布达成协议，收购 Curiosity Diagnostics 的所有已发行股。 Zoo 的所有已发行，Scope Fluidics, SA 是一家总部位于波兰华沙的医疗诊断和医疗保健市场创新技术解决方案开发商，总代价为1.7 亿美元，其中包括约1 亿美元现金。他们宣布已同意收购最大金额。

公司产品

  • ID NOW(TM) 分子平台： ID NOW 平台提供即时分子侦测。雅培实验室提供各种感染疾病感染疾病，包括呼吸道和胃肠道感染疾病。这种便携式诊断小工具可在几分钟内产生观察，从而可以快速诊断和选择治疗方法方法。
  • Cobas(R) Riat(R) 系统： Cobas(R) Riat(R) 系统是一个小型便携式平台，能够进行即时分子诊断。我们可以传染病检查，包括流感、呼吸道融合细胞病毒(RSV) 和 A 型溶血性链球菌。该技术可在 20 分钟内产生可靠的资料，从而实现快速诊断和治疗选择。
  • QIAstat-Dx： QIAstat-Dx 系统是一个完全整合的分子诊断平台，专为快速、准确的即时侦测而设计。我们提供针对呼吸道疾病、胃肠道疾病和其他感染疾病的多种测试。该设备将样品製备、扩增和检测整合在试剂盒中，并在一小时内提供结果。
  • Cepheid GeneXpert 系统： GeneXpert 系统是一个完全整合的分子诊断平台，可在护理点进行快速、准确的测试。我们提供广泛的传染病检查，包括呼吸道疾病、性行为感染和医疗保健相关感染疾病。此技术可自动进行样品製备、扩增和检测，并可在数小时内提供观察。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 资讯来源
  • 研究设计

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
    • 供应商的议价能力
    • 买方议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 业内竞争对手之间的对抗关係
  • 产业价值链分析

第五章 护理点 (POC) 基因检测市场：依技术分类

  • 介绍
  • PCR（聚合酶炼式反应）
  • 微阵列
  • 等温扩增
  • 下一代定序（NGS）
  • 其他的

第六章 护理点 (POC) 基因检测市场：依测试类型

  • 介绍
  • 职业测试
  • 诊断测试
  • 症状前和症状前测试
  • 产前检测
  • 新生儿筛检
  • 其他的

第七章 护理点 (POC) 基因检测市场：依应用分类

  • 介绍
  • 癌症筛检
  • 遗传疾病
  • 药物基因学
  • 个人化医疗
  • 其他的

第 8 章 护理点 (POC) 基因检测市场：依最终使用者分类

  • 介绍
  • 医院和诊所
  • 居家照护环境
  • 研究机构
  • 其他的

第九章 护理点 (POC) 基因检测市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 台湾
    • 其他的

第十章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞赛矩阵

第十一章 公司简介

  • ABBOTT LABORATORIES
  • F. HOFFMANN-LA ROCHE LTD
  • THERMO FISHER SCIENTIFIC INC.
  • QIAGEN NV
  • ILLUMINA, INC.
  • BIO-RAD LABORATORIES, INC.
  • BECTON, DICKINSON AND COMPANY（BD）
  • CEPHEID（A DANAHER COMPANY）
  • GRIFOLS SA
  • HOLOGIC, INC.
简介目录
Product Code: KSI061615777

The point-of-care genetic testing market is estimated to grow at a CAGR of 12.08% during the forecast period.

The point-of-care genetic testing market is rapidly expanding as technological advances bring genetic testing capabilities closer to the patient's point of care. Point-of-care genetic testing is genetic testing that is performed outside of standard laboratory settings, allowing for real-time findings and decision-making. This market category comprises a wide range of testing instruments and kits that allow healthcare practitioners to swiftly analyse genetic data and make educated treatment decisions. The rising desire for personalised treatment, early illness diagnosis, and easier access to genetic testing are propelling the point-of-care genetic testing market forward. Furthermore, developments in portable and handheld testing technologies, as well as lower genetic testing prices, are fuelling market expansion. The point-of-care genetic testing market growth presents significant prospects for revolutionising healthcare delivery, with the ability to enhance patient outcomes and allow personalised treatment methods.

Increasing Demand for Personalized and Precision Medicine in the Point-of-Care Genetic Testing Market.

The rising need for personalised and precise treatment is driving the Point-of-Care Genetic Testing market. Personalised and precision medicine is concerned with personalising medical treatments to individual patients based on genetics, lifestyle, and environmental factors. This method enables more accurate diagnosis, tailored therapy, and better treatment results. As patients and healthcare providers recognise the promise of personalised medicine to deliver more effective and personalised treatment, there is an increasing need for genetic testing technologies that can give rapid and accurate genetic information at the point of care. The ability to collect exact genetic data allows healthcare providers to make educated decisions about treatment strategies, drug selection, and preventative measures, fuelling demand for Point-of-Care Genetic Testing solutions.

Growing Awareness and Understanding of Genetic Diseases Enhances the Point-of-Care Genetic Testing Market.

Growing knowledge and understanding of genetic illnesses is a major driver of growth in the Point-of-Care Genetic Testing industry. Individuals and healthcare professionals are becoming more proactive in discovering and managing genetic diseases as public knowledge of the influence of genetic variants on health grows. Educational tools, public awareness campaigns, and genetic counselling services have all led to a better understanding of hereditary illnesses. Because of this increased knowledge, there is a greater need for Point-of-Care Genetic Testing solutions that can give rapid and accessible genetic information, supporting early diagnosis, personalised treatment regimens, and informed decision-making. The rising emphasis in healthcare on genetic illnesses has resulted in greater use of genetic testing, fuelling the growth of the Point-of-Care Genetic Testing market.

Expansion of Point-of-Care Testing Capabilities Boosts the Point-of-Care Genetic Testing Market.

The expansion of point-of-care testing capabilities is a critical driver of growth in the Point-of-Care Genetic Testing market. Point-of-care testing is the practice of running diagnostic tests close to the patient and delivering instant data that can assist urgent decision-making. The capabilities of point-of-care testing devices have grown as technology has advanced, enabling for more complex genetic testing to be performed at the point of care. This advancement allows healthcare workers to receive real-time genetic information without having to submit samples to centralized laboratories. The availability of portable and handheld diagnostic instruments capable of sophisticated genetic analysis improves convenience, decreases turnaround time, and improves patient results. The increase in point-of-care testing capabilities enables healthcare practitioners to make more prompt and informed decisions, fuelling demand for Point-of-Care Genetic Testing solutions.

North America is the Market Leader in the Point-of-Care Genetic Testing Market.

North America has emerged as the leader in the point-of-care genetic testing market. Several factors contribute to the region's dominant status. North America's healthcare system is technologically sophisticated, there is a high frequency of genetic illnesses, and there is a significant emphasis on personalised therapy. Furthermore, the area benefits from considerable expenditures in R&D, cooperation between healthcare institutions and technology firms, and favourable legislative rules that encourage the use of point-of-care genetic testing. The presence of important market companies, as well as the availability of modern testing machines and kits, contributes to North America's dominance. However, it is vital to note that the point-of-care genetic testing market size is expanding globally, and other areas such as Europe and Asia-Pacific are also seeing substantial breakthroughs in this industry.

Rapid Results and Timely Decision-Making in Point-of-Care Genetic Testing Market.

In the Point-of-Care Genetic Testing business, quick findings and rapid decision-making are critical. Traditional genetic testing sometimes necessitates transferring samples to centralised facilities, which causes delays in getting findings. Point-of-Care Genetic Testing, on the other hand, has the benefit of presenting findings quickly at the patient's location, allowing healthcare practitioners to make prompt choices. This rapid turnaround time enables quicker intervention, personalised treatment strategies, and better patient results. The capacity to acquire genetic information in a timely way improves healthcare delivery efficiency, lowers the time patients spend waiting for findings and allows for fast decision-making on treatment options, preventative measures, and counselling. Rapid findings and rapid decision-making are important motivators for the use of Point-of-Care Genetic Testing technologies in a variety of healthcare settings.n

Key Developments:

  • In August 2022, Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, announced that it has agreed to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A., a Warsaw, Poland-based developer of innovative technology solutions for the medical diagnostic and healthcare markets, for a total consideration of up to $170 million, including approximately $100 million in cash.

Company Products:

  • ID NOW™ Molecular Platform: The ID NOW platform offers point-of-care molecular testing. Abbott Laboratories provides a variety of infectious disease diagnostics, including respiratory and gastrointestinal infections. This portable diagnostic gadget generates findings in minutes, allowing for rapid diagnosis and treatment options.
  • Cobas® Liat® System: The Cobas Liat System is a small and portable platform that offers point-of-care molecular diagnostics. It provides a wide range of infectious illness tests, including influenza, respiratory syncytial virus (RSV), and Group A Streptococcus. Within 20 minutes, the technology produces trustworthy data, allowing for fast diagnosis and treatment options.
  • QIAstat-Dx: The QIAstat-Dx system is a fully integrated molecular diagnostics platform designed for point-of-care testing that is both quick and accurate. It offers several tests for respiratory, gastrointestinal, and other infectious illnesses. The device integrates sample preparation, amplification, and detection in a single cartridge and produces results in less than an hour.
  • Cepheid GeneXpert System: The GeneXpert System is a fully integrated molecular diagnostics platform that allows for speedy and precise testing at the point of care. It provides a wide range of infectious disease tests, including respiratory illnesses, sexually transmitted infections, and infections connected with healthcare. The technology automates sample preparation, amplification, and detection and produces findings in hours.

Segmentation:

By Technology

  • PCR (Polymerase Chain Reaction)
  • Microarray
  • Isothermal Amplification
  • Next-Generation Sequencing (Ngs)
  • Others

By Test Type

  • Carrier Testing
  • Diagnostic Testing
  • Predictive And Presymptomatic Testing
  • Prenatal Testing
  • Newborn Screening
  • Others

By Application

  • Cancer Screening
  • Genetic Diseases
  • Pharmacogenetics
  • Personalized Medicine
  • Others

By End-User

  • Hospitals And Clinics
  • Home Care Settings
  • Research Institutes
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Sources
  • 2.3. Research Design

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. POINT-OF-CARE GENETIC TESTING MARKET, BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. PCR (POLYMERASE CHAIN REACTION)
  • 5.3. MICROARRAY
  • 5.4. ISOTHERMAL AMPLIFICATION
  • 5.5. NEXT-GENERATION SEQUENCING (NGS)
  • 5.6. OTHERS

6. POINT-OF-CARE GENETIC TESTING MARKET, TEST TYPE

  • 6.1. Introduction
  • 6.2. CARRIER TESTING
  • 6.3. DIAGNOSTIC TESTING
  • 6.4. PREDICTIVE AND PRESYMPTOMATIC TESTING
  • 6.5. PRENATAL TESTING
  • 6.6. NEWBORN SCREENING
  • 6.7. OTHERS

7. POINT-OF-CARE GENETIC TESTING MARKET, APPLICATION

  • 7.1. Introduction
  • 7.2. CANCER SCREENING
  • 7.3. GENETIC DISEASES
  • 7.4. PHARMACOGENETICS
  • 7.5. PERSONALIZED MEDICINE
  • 7.6. OTHER

8. POINT-OF-CARE GENETIC TESTING MARKET, BY END-USER

  • 8.1. Introduction
  • 8.2. HOSPITALS AND CLINICS
  • 8.3. HOME CARE SETTINGS
  • 8.4. RESEARCH INSTITUTES
  • 8.5. OTHERS

9. POINT-OF-CARE GENETIC TESTING MARKET, BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. United States
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. United Kingdom
    • 9.4.2. Germany
    • 9.4.3. France
    • 9.4.4. Italy
    • 9.4.5. Spain
    • 9.4.6. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. Japan
    • 9.6.2. China
    • 9.6.3. India
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Taiwan
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Emerging Players and Market Lucrativeness
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

  • 11.1. ABBOTT LABORATORIES
  • 11.2. F. HOFFMANN-LA ROCHE LTD
  • 11.3. THERMO FISHER SCIENTIFIC INC.
  • 11.4. QIAGEN N.V.
  • 11.5. ILLUMINA, INC.
  • 11.6. BIO-RAD LABORATORIES, INC.
  • 11.7. BECTON, DICKINSON AND COMPANY (BD)
  • 11.8. CEPHEID (A DANAHER COMPANY)
  • 11.9. GRIFOLS S.A.
  • 11.10. HOLOGIC, INC.